
Pascal Soriot, AstraZeneca CEO, joins ‘Squawk on the Street’ to discuss why company data around its breast cancer drug was so well received, the next steps for other tumor types and more.
Pascal Soriot, AstraZeneca CEO, joins ‘Squawk on the Street’ to discuss why company data around its breast cancer drug was so well received, the next steps for other tumor types and more.